HUNTINGTON BEACH, Calif., March 14 /PRNewswire-FirstCall/ -- WayPoint Biomedical Holdings, Inc. (Pink Sheets: WYPH) has contacted and stated their position to the SEC, where WayPoint denies any and all involvement with the stock spamming incident that is the alleged cause of their temporary suspension. According to WayPoint CEO, Mr. Steven Fox, "WayPoint has never engaged in any mass e-mail stock promotion or spamming activities. We have in the past and will continue in the future, to fully support the SEC or other authorities in their investigations." Mr. Fox continues, "WayPoint applauds any and all efforts by the SEC and other regulatory bodies to locate and prosecute the perpetrators of stock spamming activities." About WayPoint Biomedical Holdings, Inc.: WayPoint Biomedical Holdings, Inc. (Pink Sheets: WYPH), is a pioneering new biomedical technology firm, specializing in tests and devices for screening and monitoring human health, wellness, fitness and environment. The Company's develops and markets a unique array of cutting-edge products, which includes their Health Essist(R) Hangover-Free Topical Patch for the Convenience Store market and their OTC approved Health Essist Drugs-of-Abuse product range. WayPoint's tests offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Wellness & Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, two of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical and their product range visit http://www.waypointbiomedical.com/, http://www.healthessist.com/, http://www.drinkdetectiveusa.com/. Included in this release are certain "forward-looking' statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law. Investor Relations: Steven Fox, 714-848-3200 E-mail: DATASOURCE: WayPoint Biomedical Holdings, Inc. CONTACT: Steven Fox of WayPoint Biomedical Holdings, Inc., +1-714-848-3200, Web site: http://www.drinkdetectiveusa.com/ Web site: http://www.healthessist.com/ Web site: http://www.waypointbiomedical.com/

Copyright